

Chris RuiWen Kuo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/456811/publications.pdf>

Version: 2024-02-01

36
papers

339
citations

840776

11
h-index

839539

18
g-index

36
all docs

36
docs citations

36
times ranked

488
citing authors

#	ARTICLE	IF	CITATIONS
1	Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1798-1801.	3.8	40
2	Scottish consensus statement on the role of FeNO in adult asthma. <i>Respiratory Medicine</i> , 2019, 155, 54-57.	2.9	34
3	Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3363-3370.	3.8	32
4	Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1714-1716.	3.8	28
5	Current appraisal of single inhaler triple therapy in COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 3003-3009.	2.3	25
6	Is small airways dysfunction related to asthma control and type 2 inflammation?. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 631-632.	1.0	23
7	I Say IOS You Say AOS: Comparative Bias in Respiratory Impedance Measurements. <i>Lung</i> , 2019, 197, 473-481.	3.3	21
8	Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics. <i>Clinical and Experimental Allergy</i> , 2020, 50, 1140-1147.	2.9	16
9	Real-life small airway outcomes in severe asthma patients receiving biologic therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2907-2909.	3.8	15
10	2020 Updated Asthma Guidelines: Clinical utility of fractional exhaled nitric oxide (Feno) in asthma management. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1281-1282.	2.9	13
11	Anti-inflammatory reliever therapy for asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 13-15.	1.0	11
12	Impulse oscillometry bronchodilator response and asthma control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3610-3612.	3.8	11
13	Anti-interleukin 13 for asthma: stick or twist?. <i>Lancet Respiratory Medicine</i> , 2018, 6, e46-e47.	10.7	9
14	COVID-19: Start with the nose. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1214.	2.9	9
15	Use of inhaled corticosteroids in asthma and coronavirus disease 2019. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 503-504.	1.0	8
16	Type 2 Asthma Inflammation and COVID-19: A Double Edged Sword. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1163-1165.	3.8	8
17	Airwave oscillometry and patient-reported outcomes in persistent asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 289-290.	1.0	7
18	Does unified allergic airway disease impact on lung function and type 2 biomarkers?. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 75.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Omaliuzumab or dupilumab for chronic rhinosinusitis with nasal polyposis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 413.	2.9	6
20	Eosinophil paradox with mepolizumab in chronic rhinosinusitis with nasal polyposis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 683.	2.9	4
21	Criteria for Airway Oscillometry Reversibility in Asthma. <i>Chest</i> , 2020, 158, 1282-1283.	0.8	3
22	Bronchoprotective tolerance with inhaled corticosteroid/long-acting β_2 -agonist treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 873.	2.9	2
23	Pragmatic evaluation of inhaled corticosteroid particle size formulations on asthma control. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1321-1327.	2.9	2
24	Non-canonical β_2 -receptor signaling. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1735.	2.9	1
25	Making simple things complicated using anti-inflammatory reliever therapy. <i>European Respiratory Journal</i> , 2020, 55, 2000267.	6.7	1
26	Systemic potency of fluticasone in asthma. <i>European Respiratory Journal</i> , 2020, 55, 2000104.	6.7	1
27	Optimal asthma control in African American children with asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2121.	3.8	1
28	Observational Data With Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist May Not Reflect Current Practice With Single Triple Inhalers. <i>Chest</i> , 2020, 157, 1045.	0.8	1
29	Inhaled triple therapy and airway hyperresponsiveness in persistent asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 597-598.	1.0	1
30	Inhaled triple therapy in chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2018, 392, 1112-1113.	13.7	0
31	Real-World Studies in Infrequently Exacerbating Patients With COPD. <i>Chest</i> , 2019, 156, 415-416.	0.8	0
32	Differences in asthma control and lung function in relation to allergic status. <i>European Respiratory Journal</i> , 2019, 53, 1802102.	6.7	0
33	Dupilumab for nasal polyposis. <i>Lancet, The</i> , 2020, 396, 233.	13.7	0
34	Diagnosing adrenal insufficiency using ACTH stimulation test. <i>European Respiratory Journal</i> , 2020, 56, 2001478.	6.7	0
35	Pneumonia Due to Inhaled Corticosteroids in COPD. <i>Chest</i> , 2020, 157, 1683-1684.	0.8	0
36	How bad is the SAD phenotype in relation to asthma control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 427.	3.8	0